• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

支付意愿中超出健康范畴的因素对质量调整生命年的影响。

Benefits beyond health in the willingness to pay for a quality-adjusted life-year.

作者信息

de Vries Linda M, Brouwer Werner B F, van Baal Pieter H M

机构信息

Erasmus School of Health Policy and Management, Department of Health Economics, Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands.

出版信息

Eur J Health Econ. 2024 Oct 7. doi: 10.1007/s10198-024-01726-7.

DOI:10.1007/s10198-024-01726-7
PMID:39375298
Abstract

Adopting a societal perspective in cost-effectiveness analysis (CEA) requires including all societal costs and benefits even if they fall outside of the realm of health and healthcare. While some benefits are not explicitly included, they might be implicitly included when people value quality-adjusted life-years (QALYs) in monetary terms. An example is utility of consumption (UoC) which has played a crucial role in discussions regarding the welfare economic underpinnings of CEA. This study investigates whether people consider elements beyond health when valuing QALYs monetarily and the influence of inclusion on this value. A Willingness to Pay (WTP) experiment was administered among the general public in which people were asked to assign monetary values to QALYs. Our results show that (stated) UoC increases with quality of life but that instructing people to consider UoC does not impact their monetary valuation of the QALY. Furthermore, many respondents consider elements beyond health when valuing QALYs but the impact on the monetary value of a QALY is limited. These findings suggest that these elements are currently not (adequately) captured in CEA. Findings also illustrate that it is difficult to isolate health from non-health benefits and to consistently capture these in CEA. With that, reconciling CEA with welfare economics remains challenging.

摘要

在成本效益分析(CEA)中采用社会视角要求纳入所有社会成本和收益,即便它们超出了健康和医疗保健领域。虽然有些收益未被明确纳入,但当人们以货币形式评估质量调整生命年(QALY)时,它们可能会被隐含地纳入。一个例子是消费效用(UoC),它在关于CEA的福利经济基础的讨论中发挥了关键作用。本研究调查了人们在以货币形式评估QALY时是否会考虑健康以外的因素以及纳入这些因素对该价值的影响。在普通公众中进行了一项支付意愿(WTP)实验,要求人们为QALY赋予货币价值。我们的结果表明,(所述的)UoC随生活质量提高,但指示人们考虑UoC并不会影响他们对QALY的货币估值。此外,许多受访者在评估QALY时会考虑健康以外的因素,但对QALY货币价值的影响有限。这些发现表明,目前CEA中并未(充分)涵盖这些因素。研究结果还表明,很难将健康与非健康收益区分开来并在CEA中始终如一地体现这些收益。因此,使CEA与福利经济学相协调仍然具有挑战性。

相似文献

1
Benefits beyond health in the willingness to pay for a quality-adjusted life-year.支付意愿中超出健康范畴的因素对质量调整生命年的影响。
Eur J Health Econ. 2024 Oct 7. doi: 10.1007/s10198-024-01726-7.
2
Willingness to pay for a QALY: theoretical and methodological issues.支付意愿以获取一个质量调整生命年:理论与方法学问题。
Pharmacoeconomics. 2005;23(5):423-32. doi: 10.2165/00019053-200523050-00002.
3
Arthroscopic Partial Meniscectomy for a Degenerative Meniscus Tear Is Not Cost Effective Compared With Placebo Surgery: An Economic Evaluation Based on the FIDELITY Trial Data.关节镜下半月板部分切除术治疗退行性半月板撕裂与安慰剂手术相比不具有成本效益:基于 FIDELITY 试验数据的经济评估。
Clin Orthop Relat Res. 2024 Sep 1;482(9):1523-1533. doi: 10.1097/CORR.0000000000003094. Epub 2024 May 7.
4
Valuing QALY gains by applying a societal perspective.从社会角度评估 QALY 获益。
Health Econ. 2013 Oct;22(10):1272-81. doi: 10.1002/hec.2879. Epub 2012 Oct 19.
5
A Contingent Valuation Study for Eliciting a Monetary Value of a Quality-Adjusted Life-Year in the General Greek Population.对一般希腊人群体进行质量调整生命年货币价值的条件价值评估研究。
Value Health Reg Issues. 2020 Sep;22:36-43. doi: 10.1016/j.vhri.2020.03.002. Epub 2020 Jul 27.
6
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.卡莫司汀植入剂与替莫唑胺治疗新诊断的高级别胶质瘤的有效性和成本效益:一项系统评价与经济学评估
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.
7
A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?对获取每质量调整生命年支付意愿的研究进行的系统评价:这是否能证明成本效益阈值的合理性?
PLoS One. 2015 Apr 9;10(4):e0122760. doi: 10.1371/journal.pone.0122760. eCollection 2015.
8
Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.质量调整生命年在儿科护理中缺乏质量:对已发表的儿童健康成本效用研究的批判性综述。
Pediatrics. 2005 May;115(5):e600-14. doi: 10.1542/peds.2004-2127.
9
Willingness to pay per quality-adjusted life year for life-saving treatments in Thailand.泰国为挽救生命的治疗所支付的每质量调整生命年的意愿。
BMJ Open. 2015 Oct 5;5(10):e008123. doi: 10.1136/bmjopen-2015-008123.
10
Estimating the monetary value of health: why and how估算健康的货币价值:原因与方法

本文引用的文献

1
The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice.健康的价值在成本效益分析中的体现:理论与实践。
Pharmacoeconomics. 2023 Jun;41(6):607-617. doi: 10.1007/s40273-023-01265-8. Epub 2023 Apr 18.
2
Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression.支付意愿以获得质量调整生命年:系统综述和荟萃回归分析。
Eur J Health Econ. 2022 Mar;23(2):277-299. doi: 10.1007/s10198-021-01364-3. Epub 2021 Aug 21.
3
Future Costs in Cost-Effectiveness Analyses: Past, Present, Future.
成本效益分析中的未来成本:过去、现在、未来。
Pharmacoeconomics. 2019 Feb;37(2):119-130. doi: 10.1007/s40273-018-0749-8.
4
When is it too expensive? Cost-effectiveness thresholds and health care decision-making.何时成本过高?成本效益阈值与医疗保健决策。
Eur J Health Econ. 2019 Mar;20(2):175-180. doi: 10.1007/s10198-018-1000-4.
5
A Stated Preference Approach to Assess whether Health Status Impacts on Marginal Utility of Consumption.一种用于评估健康状况是否会影响消费边际效用的陈述偏好方法。
Health Econ. 2017 Oct;26(10):1224-1233. doi: 10.1002/hec.3393. Epub 2016 Aug 11.
6
Should Cost-Effectiveness Analysis Include The Cost Of Consumption Activities? An Empirical Investigation.
Value Health. 2014 Nov;17(7):A370. doi: 10.1016/j.jval.2014.08.838. Epub 2014 Oct 26.
7
The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature.支付意愿以获取质量调整生命年:实证文献综述。
Health Econ. 2015 Oct;24(10):1289-1301. doi: 10.1002/hec.3085. Epub 2014 Jul 28.
8
WTP for a QALY and health states: More money for severer health states?质量调整生命年(QALY)和健康状态的支付意愿:更愿意为更严重的健康状态支付更多的钱?
Cost Eff Resour Alloc. 2013 Sep 1;11:22. doi: 10.1186/1478-7547-11-22. eCollection 2013.
9
Productivity costs in economic evaluations: past, present, future.经济评估中的生产力成本:过去、现在、未来。
Pharmacoeconomics. 2013 Jul;31(7):537-49. doi: 10.1007/s40273-013-0056-3.
10
Valuing QALY gains by applying a societal perspective.从社会角度评估 QALY 获益。
Health Econ. 2013 Oct;22(10):1272-81. doi: 10.1002/hec.2879. Epub 2012 Oct 19.